

## Special Issue

# Molecular Pathology of Cancer: The Past, the Present, and the Future

### Message from the Guest Editor

I would like to invite you to contribute manuscripts for a Special Issue in the Journal of Personalized Medicine covering the past, the present, and the future of molecular pathology in oncology. Molecular pathology is transforming clinical pathology and contributes to establishing a histopathological diagnosis and disease classification, provides prognostic information, identifies targets for therapy, and reveals mechanisms of resistance to therapy. This Special Issue on the molecular pathology of cancer aims to provide an overview of different aspects of clinical molecular pathology and encompasses all oncologic and hemato-oncologic diseases. Contributions may address the description of the molecular mechanism of neoplastic diseases in association with their clinical utility, the role of molecular pathology in personalized oncology, laboratory techniques and assays in molecular pathology, bioinformatics, quality control, and potential ethical and legal considerations. Case reports, reviews, and original research articles are welcome.

---

### Guest Editor


Dr. Leonhard Müllauer

Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria

---

### Deadline for manuscript submissions

closed (15 November 2020)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/41112](https://mdpi.com/si/41112)

*Journal of Personalized  
Medicine*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).